Your basket is currently empty!
» Kidney Cancer News » Molecular markers to PREDICT drug response in kidney cancer patients
Molecular markers to PREDICT drug response in kidney cancer patients
(ongoing until 2015)
Are you interested in taking part in a clinical trial in London investigating the use of molecular markers to predict response to sunitinib and/or everolimus? If you want to find out more, please call James Larkin on 020 7808 2132. Alternatively, please use our Contact Form and we will pass on your request. More details are available here.
Kidney Cancer UK
Kidney Cancer UK is the UK’s leading kidney cancer charity. We seek to reduce the harm caused by kidney cancer by increasing knowledge and awareness, providing patient information and by supporting research into the causes, prevention and treatment of the disease
Donate
With your help we can beat kidney cancer together
